COMMUNIQUÉS West-GlobeNewswire

Iantrek Announces 1-Year Clinical Results of Its Bio-Interventional Technology for Uveoscleral Outflow Enhancement in Open-Angle Glaucoma Patients

17/09/2024 - 14:00

WHITE PLAINS, N.Y., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Iantrek, Inc., a venture-backed medical technology company pioneering next-generation bio- and micro-interventional approaches for ophthalmic disease treatment, [...]

CAMP4 Therapeutics Secures Orphan Drug Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders

17/09/2024 - 14:00

CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics, a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with [...]

Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar

17/09/2024 - 14:00

HAYWARD, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based [...]

Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial

17/09/2024 - 14:00

Study arm initiated based upon enthusiasm and at the request of investigators who participated in first-line cholangiocarcinoma cohort BASKING RIDGE, N.J., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. ( [...]

Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics

17/09/2024 - 14:00

BOSTON and LONDON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the [...]

ImmuneSensor Therapeutics Granted New U.S. Patent for its Oral cGAS Inhibitors

17/09/2024 - 14:00

Composition and methods patent granted claims covering compounds for treating broad range of inflammatory and autoimmune diseases and built on foundational intellectual property for the discovery of the cGAS pathway [...]

Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer

17/09/2024 - 14:00

Industry veteran brings multidisciplinary expertise leading Mass Spectrometry division at Agilent Technologies to a company building a platform to power next-generation proteomics SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE [...]

Atsena Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis

17/09/2024 - 13:30

Marks second FDA designation for ATSN-201, which previously received Rare Pediatric Disease designation DURHAM, N.C., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused [...]

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

17/09/2024 - 13:30

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA

17/09/2024 - 13:30

- Breakthrough Therapy Designation was granted based on preliminary clinical evidence from the PROPEL 2 clinical trial, meeting the FDA’s requirement of potentially demonstrating substantial improvement in efficacy over [...]

Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration

17/09/2024 - 13:30

Companies will jointly research DNA-damage response kinase targets to identify potential drug candidates for the treatment of cancer VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics [...]

Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications

17/09/2024 - 13:00

Treatment with OTX-2002 led to controlled downregulation of MYC gene expression and resulted in significant inhibition of tumor growth as a monotherapy and in combination with standard of care agents in preclinical [...]

Eversense 365 Receives FDA Clearance: The World’s First One Year CGM

17/09/2024 - 13:00

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with [...]

Merit Medical Signs Agreement to Purchase Lead Management Portfolio from Cook Medical

17/09/2024 - 13:00

Asset acquisition of Cook Medical’s end-to-end lead management product portfolio strengthens Merit’s existing electrophysiology and CRM business Asset acquisition projected to add approximately $40 million of revenue, [...]

BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks

17/09/2024 - 13:00

INTENDED FOR CANADIAN AUDIENCES ONLY TORONTO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it successfully completed negotiations with the pan-Canadian [...]

BioCryst et l’Alliance pharmaceutique pancanadienne concluent avec succès les négociations au sujet de ORLADEYO (bérotralstat), un traitement oral à prise uniquotidienne pour la prévention des crises d’angio-œdème héréditaire

17/09/2024 - 13:00

RÉSERVÉ À UN PUBLIC CANADIEN TORONTO, 17 sept. 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq : BCRX) a annoncé aujourd’hui l’aboutissement des négociations avec l’Alliance pharmaceutique pancanadienne [...]

ADMA Biologics Set to Join S&P SmallCap 600 Index

17/09/2024 - 13:00

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and [...]

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

17/09/2024 - 13:00

WAYNE, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today [...]

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

17/09/2024 - 13:00

Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of CLN-978 for patients with systemic lupus erythematosus The trial will be conducted in multiple sites in [...]